Neuro-Oncology Reviews
Volume
27 Number 32
20 November 2025
Home > Publications > Neuro-Oncology Reviews > Volume 27, Year 2025 > Number 32, 20 November
Xu M, An Y, Liu X, Li X, Huang X, Gu Q, Xue M, Xue J, Tao L, Shan
H, Chen X, Zhang M.
The molecular
mechanisms of cuproptosis and its role in central nervous system
diseases.
Cell
Signal. 2025 Nov 10;138:112236. doi:
10.1016/j.cellsig.2025.112236. PMID:
41224164. Review˰
ˍ
Ge Z, Jin G, Wang H, Wang S, Fei X, Li S, Zhang L, Jiang X, Zhang
Y.
Risk factors for postoperative
malignant progression of lower-grade gliomas: a systematic review
and meta-analysis.
Surg
Oncol. 2025 Nov 12;64:102327. doi:
10.1016/j.suronc.2025.102327. PMID:
41242200. Review;
Meta-Analysis˰
ˍ
Basaran AE, Wellkisch AC, Güresir E, Wach J.
Extent
of reoperation predicts survival in recurrent IDH-wildtype
glioblastoma based on institutional data and individual patient
data meta analysis.
Discov
Oncol. 2025 Nov 13;16(1):2099. doi:
10.1007/s12672-025-03928-8. PMID:
41231323. Meta analysis. ˍ
Pristo EL, Hotchkiss KM, Corcoran AM, Noldner P, Okada H, Hickey
JW, Conejo-Garcia J, Shaz B, Khasraw M.
The
promise of TIL therapy for glioblastoma.
Trends
Cancer. 2025 Nov 13:S2405-8033(25)00254-7. doi:
10.1016/j.trecan.2025.10.003. PMID:
41238472. Review˰
ˍ
Wo XW, Zhu HF, Xu N.
Dynamic
susceptibility contrast perfusion in differentiation between
recurrence and pseudoprogression in glioblastoma: a systematic
review and meta-analysis.
Quant
Imaging Med Surg. 2025 Nov 14;15(12):12336-12345. doi:
10.21037/qims-2025-245. PMID:
41367751. Review; Meta-analysis. ˍ
Trejo-Solís C, Rojas-Tomé IS, Jung-Cook H,
Palomares-Alonso F.
Melatonin combined
with antineoplastic drugs or natural products for cancer
treatment: An update.
Curr
Res Pharmacol Drug Discov. 2025 Nov 17;9:100239. doi:
10.1016/j.crphar.2025.100239. PMID:
41341468. Review. ˍ
Huang M, Li J, Liu B, Liao Y, Wang B, Liu H, Liu Y, Zhao J.
Non-WNT/non-SHH medulloblastoma in
siblings: case report and literature review.
Discov
Oncol. 2025 Nov 20. doi:
10.1007/s12672-025-04038-1. PMID:
41264133. Case report; Review. ˍ
Santos MDC, Rodrigues NMV, Gibram F, Gouhie FA, Campos ACP, de
Assis DV, Formentin C, Feher O, de Souza E Silva ARN, Hanna SA,
Chung C, Barbosa CC, Moraes FY, Maldaun MVC.
Adjuvant
chemoradiotherapy with procarbazine, lomustine, and vincristine
(PCV) or temozolomide for 1p/19q Co-deleted anaplastic
oligodendroglioma: a systematic review and network meta-analysis.
BMC
Cancer. 2025 Nov 18;25(1):1779. doi:
10.1186/s12885-025-15085-w. PMID:
41254593. Review; Meta-Analysis.
ˍ
Adefolaju A, Kram DE, Mann B, Hingtgen S, Satterlee A.
Informing
development of brain cancer therapies within "preclinical
trials" using ex vivo patient tumors.
Adv
Drug Deliv Rev. 2025 Nov 19;228:115736. doi:
10.1016/j.addr.2025.115736. PMID:
41270976. Review. ˍ
Fawzy M, ElTayebi HM, Samir A.
Exploring
Neural Stem Cell Therapies as Innovative Treatments for
Glioblastoma.
Cell
Mol Neurobiol. 2025 Nov 20;45(1):108. doi:
10.1007/s10571-025-01619-0. PMID:
41264121. Review. ˍ
Mezzari MHDS, Lima NL, Maggi BG, Grüdtner DOM, de Souza JCS,
de Lara LHC, Isolan GR.
Regorafenib in
adult patients with recurrent glioblastoma: a single-arm
meta-analysis.
J
Chemother. 2025 Nov 20:1-12. doi:
10.1080/1120009X.2025.2591474. PMID:
41263675. Meta
analysis˰ ˍ